Funding Arrangement - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Apr. 30, 2021	Jul. 31, 2019	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Funding Arrangement [Line Items]
Grant income			$ 1,931	$ 1,585	$ 2,478
Cost Reimbursement Sub-Award Agreement
Funding Arrangement [Line Items]
Funding period of award to develop universal vaccine to prevent infections caused by Group A Strep bacteria		4 years
Potential funding amount of award to develop vaccine to prevent shingella infections	$ 500
Grant income			1,900	1,600	$ 2,500
Cost Reimbursement Sub-Award Agreement | Maximum
Funding Arrangement [Line Items]
Initial funding committed by award		$ 1,600
Total funding committed by award, available upon achievement of development milestones		15,100
Potential funding period of award to develop vaccine to prevent shingella infections	5 years
CARB-X Agreement
Funding Arrangement [Line Items]
Grant receivable on unreimbursed, eligible costs incurred			$ 1,000	$ 1,200
Potential funding committed by award		14,600
CARB-X Agreement | Maximum
Funding Arrangement [Line Items]
Initial funding committed by award		29,700
Potential funding committed by award		29,700
CARB-X Agreement | Minimum
Funding Arrangement [Line Items]
Potential funding committed by award		$ 6,600